Details of Drug-Drug Interaction
| Drug General Information (ID: DDIC7LIWP3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Flucytosine | Drug Info | Givosiran | Drug Info | |||||
| Drug Type | Small molecule | Small interfering RNA | |||||||
| Therapeutic Class | Antifungal Agents | Metabolic Agents | |||||||
| Structure | |||||||||
| Mechanism of Flucytosine-Givosiran Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Decreased renal excretion due to nephrotoxicity Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Flucytosine | Givosiran | |||||||
| Mechanism | Primarily eliminated by renal excretion | Nephrotoxicity | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Nephrotoxicity | ||||||||
| Factor Description | Drug-induced nephrotoxicity is a common and potentially serious complication of medication use. The kidneys are the primary organ for drug excretion, and when they are damaged can lead to decreased drug excretion. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides polypeptide, glycopeptide, and polymyxin antibiotics amphotericin B adefovir cidofovir tenofovir foscarnet cisplatin deferasirox gallium nitrate lithium mesalamine certain immunosuppressants intravenous bisphosphonates intravenous pentamidine high intravenous dosages of methotrexate high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Ancobon (flucytosine). Roche Laboratories, Nutley, NJ. | ||||||||||||||||||